Controversy surrounds Exondys 51 approval: What to knowNew medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.
Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patientsCost burden prompts payers to consider appropriate utilization
Hep C drugs approved for kidsFDA approved supplemental applications for 2 primary hepatitis C medications to be used in children for the first time.
Watch list 2016: Top therapeutic areas
Watch list 2016: Top therapeutic areasExperts say you should follow these 6 therapeutic areas.
FDA approves Harvoni for new usesFDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.
FDA approves Daklinza for hepatitis C genotype 3On July 24, FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections.
Harvoni could save US, Europe $3.2 billionThe higher cure rate of treating hepatitis C patients with a combination of ledipasvir and sofosbuvir (Harvoni) led to substantially better work productivity, according to a new study. In fact, improved work productivity and lack of absenteeism could save the United States and 5 European countries more than $3.2 billion a year.
FDA approves changes to hep C drug label to include new warningsFDA has approved changes to the hepatitis C antiviral simeprevir (Olysio, Janssen) label to include new warnings about serious symptomatic bradycardia—slowing of the heart rate—when co-administered with antiarrhythmic drug amiodarone and antiviral sofosbuvir (Solvaldi, Gilead).
New hep C drugs will strain the system: MD Anderson studyThe cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies is likely to place a tremendous economic burden on the country’s healthcare system, according to a study published in the March 17 issue of the Annals of Internal Medicine.
FDA warns about serious reactions to Harvoni, SovaldiBoth the Food and Drug Administration (FDA) and Harvoni and Sovaldi maker Gilead are warning Hepatitis C patients about serious bradycardia when the drugs are combined with certain other medications.